Murphy - Figure 14
Hypothesis
FIG. 14: On the basis of the preceding observations, the HOT-HMV trial was devised to assess home NIV therapy versus HMV.[1] The aim was to target the subset of patients with chronic respiratory failure for home NIV, with the aim of abolishing nocturnal hypoventilation and improving admission-free survival for an acute life-threatening exacerbation of COPD in patients with persisting hypercapnia, thus demonstrating that this group is distinct from the population recruited into the RESCUE trial, who received no benefit from home NIV, as discussed in Figures 10–13.[13]
References
Murphy P, Arbane G, Bourke S, et al. Effect of home non-invasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized controlled trial. JAMA. In press.
Struik FM, Sprooten RT, Kerstjens HAM, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomized, controlled, parallel-group study. Thorax. 2014;69:826−34. doi: 10.1136/thoraxjnl-2014-205126.